Form 4 for ORMP ORAMED PHARMACEUTICALS INC.
Accepted 2025-01-06 00:00:00 ET · period of report 2025-01-02 · accession 0001213900-25-001166 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-01-06 | 2025-01-02 | ORMP | Gabay Avraham | CFO | A - Grant | — | +188.0K | 358.0K | +111% | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-01-02 | A | A | 188,000 | — | 358,040 | D | — | — | (F1) Represents Restricted Stock Units ("RSUs") that will vest in quarterly installments of approximately 15,666 over a three year period starting January 1, 2025. The RSUs convert into the Issuer's Common Stock on a one-for-one basis. |